Bailard Inc. Buys 317 Shares of Colgate-Palmolive (NYSE:CL)

Bailard Inc. boosted its stake in shares of Colgate-Palmolive (NYSE:CL) by 4.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,192 shares of the company’s stock after acquiring an additional 317 shares during the quarter. Bailard Inc.’s holdings in Colgate-Palmolive were worth $653,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. &PARTNERS boosted its stake in shares of Colgate-Palmolive by 0.7% during the 4th quarter. &PARTNERS now owns 17,643 shares of the company’s stock worth $1,406,000 after acquiring an additional 129 shares in the last quarter. West Branch Capital LLC boosted its stake in shares of Colgate-Palmolive by 24.0% during the 4th quarter. West Branch Capital LLC now owns 682 shares of the company’s stock worth $54,000 after acquiring an additional 132 shares in the last quarter. First Foundation Advisors boosted its stake in shares of Colgate-Palmolive by 2.7% during the 3rd quarter. First Foundation Advisors now owns 5,226 shares of the company’s stock worth $372,000 after acquiring an additional 136 shares in the last quarter. Waldron Private Wealth LLC boosted its stake in shares of Colgate-Palmolive by 2.7% during the 3rd quarter. Waldron Private Wealth LLC now owns 5,361 shares of the company’s stock worth $381,000 after acquiring an additional 140 shares in the last quarter. Finally, Autumn Glory Partners LLC boosted its stake in shares of Colgate-Palmolive by 2.7% during the 4th quarter. Autumn Glory Partners LLC now owns 5,319 shares of the company’s stock worth $424,000 after acquiring an additional 140 shares in the last quarter. 80.41% of the stock is owned by institutional investors.

Insider Transactions at Colgate-Palmolive

In other news, Director C Martin Harris sold 2,760 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $84.50, for a total transaction of $233,220.00. Following the completion of the sale, the director now owns 19,272 shares in the company, valued at approximately $1,628,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Noel R. Wallace sold 50,000 shares of Colgate-Palmolive stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $83.15, for a total value of $4,157,500.00. Following the completion of the sale, the chief executive officer now owns 274,179 shares in the company, valued at approximately $22,797,983.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director C Martin Harris sold 2,760 shares of Colgate-Palmolive stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $84.50, for a total transaction of $233,220.00. Following the completion of the sale, the director now owns 19,272 shares of the company’s stock, valued at approximately $1,628,484. The disclosure for this sale can be found here. Insiders sold 232,371 shares of company stock worth $19,505,099 in the last 90 days. Insiders own 0.34% of the company’s stock.

Colgate-Palmolive Trading Up 1.9 %

CL opened at $91.01 on Friday. The company has a debt-to-equity ratio of 8.59, a current ratio of 1.11 and a quick ratio of 0.71. The company’s 50 day simple moving average is $87.66 and its two-hundred day simple moving average is $81.54. Colgate-Palmolive has a 1-year low of $67.62 and a 1-year high of $92.25. The firm has a market capitalization of $74.81 billion, a price-to-earnings ratio of 32.74, a price-to-earnings-growth ratio of 3.35 and a beta of 0.42.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, April 26th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.96 billion. Colgate-Palmolive had a net margin of 11.82% and a return on equity of 509.75%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $0.73 EPS. Analysts expect that Colgate-Palmolive will post 3.5 EPS for the current fiscal year.

Colgate-Palmolive Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 22nd will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, April 19th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.20%. This is an increase from Colgate-Palmolive’s previous quarterly dividend of $0.48. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 71.94%.

Wall Street Analyst Weigh In

CL has been the topic of several recent analyst reports. Wells Fargo & Company increased their target price on shares of Colgate-Palmolive from $80.00 to $88.00 and gave the stock an “equal weight” rating in a research note on Monday, January 29th. Citigroup increased their target price on shares of Colgate-Palmolive from $95.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, April 16th. JPMorgan Chase & Co. raised their price target on shares of Colgate-Palmolive from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, January 18th. The Goldman Sachs Group began coverage on shares of Colgate-Palmolive in a research note on Friday, March 1st. They issued a “buy” rating and a $93.00 price target on the stock. Finally, Barclays raised their price target on shares of Colgate-Palmolive from $82.00 to $84.00 and gave the company an “equal weight” rating in a research note on Friday, April 12th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, Colgate-Palmolive currently has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.